Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest (1999) 3.21

Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol (2009) 2.15

Beta-interferons in multiple sclerosis: a single center experience in India. Ann Indian Acad Neurol (2010) 1.03

Fatigue in multiple sclerosis persists over time: a longitudinal study. J Neurol (2006) 1.02

Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol (2008) 1.01

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol (2013) 1.01

Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PLoS One (2011) 0.96

Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. Brain (2015) 0.90

Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implications. Cerebrospinal Fluid Res (2005) 0.88

Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS One (2012) 0.87

Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry. J Clin Immunol (2005) 0.87

Diagnostic and Prognostic Value of the Cerebrospinal Fluid Concentration of Immunoglobulin Free Light Chains in Clinically Isolated Syndrome with Conversion to Multiple Sclerosis. PLoS One (2015) 0.78

Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. Mult Scler Int (2015) 0.77

Interferon beta1a treatment modulates TH1 expression in gammadelta + T cells from relapsing-remitting multiple sclerosis patients. J Clin Immunol (2001) 0.75

Axonal transection in the lesions of multiple sclerosis. N Engl J Med (1998) 12.21

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39

The functional independence measure: a new tool for rehabilitation. Adv Clin Rehabil (1987) 4.86

Using formative research to lay the foundation for community level HIV prevention efforts: an example from the AIDS Community Demonstration Projects. Public Health Rep (1996) 4.82

Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med (2001) 4.63

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum (2001) 4.60

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50

Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41

HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J (1997) 3.99

Interrater reliability of the 7-level functional independence measure (FIM) Scand J Rehabil Med (1994) 3.86

Neuroreality I. Dedicated demolition of the Decade of the Brain: the genuine threat to neurologic research from the animal radical right. The American Academy of Neurology Animal Studies Subcommittee. Neurology (1995) 3.77

The reliability of the functional independence measure: a quantitative review. Arch Phys Med Rehabil (1996) 3.41

The structure and stability of the Functional Independence Measure. Arch Phys Med Rehabil (1994) 3.30

Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest (1999) 3.21

Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med (1972) 3.09

A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98

The Functional Independence Measure: tests of scaling assumptions, structure, and reliability across 20 diverse impairment categories. Arch Phys Med Rehabil (1996) 2.86

Light and electron microscopic observations on Rosenthal fibers in Alexander's disease and in multiple sclerosis. J Neuropathol Exp Neurol (1970) 2.85

Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil (1979) 2.64

Frontal lobe injuries, violence, and aggression: a report of the Vietnam Head Injury Study. Neurology (1996) 2.55

Cellular differentiation of the immune system of mice. I. Separate splenic antigen-sensitive units for different types of anti-sheep antibody-forming cells. J Exp Med (1968) 2.51

Interferon-induced antiviral actions and their regulation. Adv Virus Res (1993) 2.40

Effectiveness of HIV prevention interventions in developing countries. AIDS (2000) 2.35

Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol (1984) 2.21

The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care (2007) 2.17

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology (1998) 2.16

Sensationalism in the media: when scientists and journalists may be complicit collaborators. Eff Clin Pract (2001) 2.14

Outcome of comprehensive medical rehabilitation: measurement by PULSES profile and the Barthel Index. Arch Phys Med Rehabil (1979) 2.14

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology (2009) 2.10

Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol (1991) 2.08

Squamous cell carcinoma of the renal pelvis associated with urinary diversion and humoral hypercalcaemic malignancy syndrome. J R Coll Surg Edinb (1991) 2.04

Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci (1989) 2.01

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol (1998) 1.97

Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2001) 1.96

Effectiveness of assistive technology and environmental interventions in maintaining independence and reducing home care costs for the frail elderly. A randomized controlled trial. Arch Fam Med (1999) 1.94

Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem (1996) 1.92

Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood (2000) 1.90

Etiology of progressive multifocal leukoencephalopathy. Identification of papovavirus. N Engl J Med (1973) 1.90

Risking everything? Risk behavior, behavior change, and AIDS. Science (1994) 1.89

Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke (1997) 1.89

NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology (2010) 1.88

Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol (1997) 1.88

Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol (1996) 1.84

A case-mix classification system for medical rehabilitation. Med Care (1994) 1.84

Viral infections and demyelinating diseases. N Engl J Med (1973) 1.84

Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 1.83

Eight-year follow-up study of brain atrophy in patients with MS. Neurology (2002) 1.78

Glutamic acid: selective depletion by viral induced granule cell loss in hamster cerebellum. Brain Res (1974) 1.77

Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76

Functional status measures in a comprehensive stroke care program. Arch Phys Med Rehabil (1977) 1.76

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology (2012) 1.76

Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J Immunol (1998) 1.72

Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol (2000) 1.71